Omada partners with Lilly for Zepbound programs

Obesity care is turning into a distribution fight. Not a science fight — Lilly already has Zepbound, and demand is there. The bottleneck is who pays, who prescribes, and who keeps patients on treatment long enough for the drug to work. That is why Omada Health joining Lilly’s Employer Connect matters now. ### What actually changed? On May 7, Omada said it will serve as an independent program administrator inside Lilly’s Employer Connect platform, which launched in March. That means employers can use Omada’s GLP-1 Care Track to evaluate workers, prescribe Zepbound when appropriate, and manage patients over time instead of just handing over a drug benefit and hoping for the best. (omadahealth.com) ### What is Lilly Employer Connect? Basically, it is Lilly’s attempt to route around the mess of uneven insurance coverage for obesity drugs. Employer Connect links employers to administrators and pharmacy options so companies can set defined contribution levels and get more predictable pricing for Zepbound. (omadahealth.com)ible depending on the benefit design. (prnewswire.com) ### Why does Omada fit here? Omada is not just a telehealth prescriber. Its pitch is that medication works better when it sits inside a broader behavior-change program — coaching, monitoring, and support before, during, and after GLP-1 use. In its announcement, Omada framed the Lilly tie-up as another access path alongside PBM integrations and its own cash-pay GLP-1 Flex Care option. In other words, Omada wants to be the operating layer between the employer budget and the patient journey. (omadahealth.com) ### Why are employers the battleground? Because employers are stuck with a nasty tradeoff. GLP-1 drugs can be clinically effective, but they are expensive, long-duration therapies, and coverage has been inconsistent. Omada’s release points to rising budget pressure and patchy access. Lilly’s answer is not un(omadahealth.com)open-ended pharmacy spend. (omadahealth.com) ### Where does the Phlo and Holland & Barrett deal fit? It shows the same pattern in a different market. In the UK, Holland & Barrett is using Phlo to power a weight-management service across stores and online, while Phlo handles clinical assessment, prescribing, dispensing, and patient support. So the model is spreading: consumer brand up front, clinical and pharmacy infrastructure underneath, and obesity treatment packaged as a guided service rather than a standalone prescription. (weightloss.services.hollandandbarrett.com) ### Why does that matter beyond one drug? Because the real product is becoming managed access. Pharma companies want more patients on therapy. Employers and retailers want predictable cost and lower operational hassle. Digital health companies want to own adherence, coaching, and follow-up — the boring middle that determines whether a patient stays on treatment. The winner may not (weightloss.services.hollandandbarrett.com)buy, govern, and stick with. (omadahealth.com) ### What is the catch? The catch is that these programs solve access friction, not the whole obesity-care problem. They can simplify prescribing and payment, but they still depend on employer willingness to subsidize treatment and on patients staying engaged over time. If employers decide even defined-contri(omadahealth.com). (omadahealth.com) ### Bottom line This is Lilly, Omada, and now retailers like Holland & Barrett testing the same idea from different angles: don’t just sell the GLP-1 — sell the pathway. If that works, obesity treatment starts to look less like a pharmacy benefit and more like a managed service. (omadahealth.com)